Literature DB >> 9813163

Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas.

I B Efanova1, S V Zaitsev, A M Efanov, C Ostenson, A Raap, H Mest, P Berggren.   

Abstract

The effects of the imidazoline compound RX871024 on arginine-induced insulin, glucagon, and somatostatin secretion in the isolated perfused rat pancreas have been investigated. Arginine induced biphasic insulin, glucagon, and somatostatin release when infused for 20 min at 20 mM concentration and 3.3 mM glucose in the medium. RX871024, at 10 microM, did not influence basal hormone secretion but enhanced arginine-stimulated insulin and somatostatin release. In contrast, glucagon secretion was markedly inhibited by 10 microM imidazoline. RX871024 (1 microM) did not significantly affect arginine-induced insulin and somatostatin secretion but had an inhibitory effect on the second phase of glucagon release. In conclusion, RX871024 exerts a complex effect on the endocrine pancreas challenged by arginine, comprising stimulation of insulin and somatostatin release and inhibition of glucagon release. These effects on hormone release probably constitute the main mechanism of the antidiabetogenic action of the imidazolines. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813163     DOI: 10.1006/bbrc.1998.9635

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Multiple effector pathways regulate the insulin secretory response to the imidazoline RX871024 in isolated rat pancreatic islets.

Authors:  M Mourtada; S L Chan; S A Smith; N G Morgan
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  The imidazoline NNC77-0020 affects glucose-dependent insulin, glucagon and somatostatin secretion in mouse pancreatic islets.

Authors:  Marianne Høy; Hervør L Olsen; Krister Bokvist; Jacob S Petersen; Jesper Gromada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-06       Impact factor: 3.000

3.  The imidazoline compound RX871024 promotes insulinoma cell death independent of AMP-activated protein kinase inhibition.

Authors:  Irina I Zaitseva; Sergei V Zaitsev; Per-Olof Berggren
Journal:  Invest New Drugs       Date:  2016-05-25       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.